DS
DMK

David Shaw’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

David Shaw’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-152
Closed -$34K – 4048
2018
Q2 		$34K Buy
+152
New +$40.7K ﹤0.01% 3659

Other funds holding DMK

First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

David Shaw's DMK Position: Q3 2018 in Review

David Shaw sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q3 2018, closing a stake of 152 shares — an estimated $34K sold.

David Shaw first reported a position in DMK in Q2 2018 and held it in 1 quarter. The position peaked at $34K in Q2 2018. 57 funds tracked by Wall St. Rank hold DMK as of Q3 2018.

  • David Shaw reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q3 2018 after selling out during the quarter.
  • David Shaw sold 152 DMK Pharmaceuticals Corporation Common Stock shares in Q3 2018, an estimated $34K.
  • David Shaw first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q2 2018 and held it in 1 quarter.
  • David Shaw's DMK Pharmaceuticals Corporation Common Stock position peaked at $34K in Q2 2018.
  • 57 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q3 2018.

Based on D.E. Shaw & Co's 13F filing for Q3 2018, filed 14 Nov 2018.